Globally, these findings indicate that VIRMA depletion mitigates cancer progression by decreasing m6A RNA methylation levels in PCa, similarly to other cancer types, such as gastric, breast and hepatocellular carcinomas [23,37,38]. Here, VIRMA is linked to posterior cortical atrophy.